Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Vaxigrip
Inactivated Split-virion influenza vaccine · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Lot 1 |
| 2 | EXPERIMENTAL | Lot 2 |
| 3 | EXPERIMENTAL | Lot 3 |
| 4 | ACTIVE_COMPARATOR | Control |
| Name | Type | Description |
|---|---|---|
| Inactivated Split-virion influenza vaccine | BIOLOGICAL | Vaccine Lot 1 |
Inclusion Criteria : * Aged 18 to 60 years on the day of inclusion. * Informed consent form signed. * Able to attend all scheduled visits and to comply with all trial procedures. * For a woman, inability to bear a child or negative urine pregnancy test at the first visit. Exclusion Criteria : * S...
The inactivated split-virion influenza vaccine is a vaccine developed by Sanofi for protection against influenza, an infection caused by viruses in the Orthomyxoviridae family. It is an injectable vaccine that uses inactivated, split virus particles and is given to healthy adults. It is currently an investigational product in Phase 3 development.
It is used for the prevention of influenza, listed in development for Orthomyxoviridae infection. Influenza is a respiratory illness caused by influenza viruses. The vaccine is designed to stimulate an immune response against the virus in adults aged 18 years and older. Its clinical program enrolled healthy adult volunteers.
Sanofi develops the inactivated split-virion influenza vaccine. Sanofi trades on the New York Stock Exchange under the ticker SNY. The company is the sponsor of the vaccine's clinical development program in infectious disease.
The inactivated split-virion influenza vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been established as approved. Its Phase 3 trial has been completed, and no trials for this asset are currently listed as active.
The vaccine has been studied in one completed Phase 3 trial, NCT00383539, titled a lot-to-lot consistency study of the investigational, inactivated, split-virion influenza vaccine in adults. That randomized, double-blind, active-controlled trial enrolled 2,256 healthy adults aged 18 years and older across France, Lithuania, Spain, and the United Kingdom.